Ambrx Biopharma Inc.
AMAMNYSEHealthcare
$28.00
+$0.02(+0.07%)
Market Cap$1.8B
P/E Ratio—
52W High$28.15
52W Low$6.55
Ambrx Biopharma Inc. (AMAM) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
AMAM · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2023Report Date: Nov 16, 2023EPS Actual
-$0.37
Est. -$0.19 · -94.7%
Revenue
$0.00B
Fiscal Period
Q4 FY2023
FY ends December
Report Date
Nov 16, 2023
After Market Close
▼ Miss EPS
AMAM reports quarterly as a NYSE-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.00
Rev. $1.80B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.00
Rev. Est.$1.80B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▼ Q4 FY2023 | Nov 16, 2023 | -$0.19 | -$0.37 | -94.7% | $0.00B | — | — |
| ▼ Q3 FY2023 | Aug 9, 2023 | -$0.09 | -$0.35 | -288.9% | $0.00B | — | — |
| — Q2 FY2023 | May 11, 2023 | — | -$0.05 | — | $0.00B | — | — |
| — Q2 FY2023 | Apr 25, 2023 | — | -$0.34 | — | $0.00B | — | — |
| — Q3 FY2022 | Sep 30, 2022 | — | -$0.34 | — | $0.00B | — | — |
| ▼ Q3 FY2022 | Aug 29, 2022 | -$0.08 | -$1.33 | -1562.5% | $0.00B | — | — |
| ▼ Q2 FY2022 | Apr 26, 2022 | -$0.08 | -$1.04 | -1195.3% | $0.00B | — | — |
| — Q1 FY2022 | Mar 31, 2022 | — | -$0.59 | — | $0.00B | — | — |
Q4 FY2023
Nov 16, 2023Miss
EPS Actual
-$0.37
EPS Est.
-$0.19
EPS Surpr.
-94.7%
Revenue
$0.00B
Q3 FY2023
Aug 9, 2023Miss
EPS Actual
-$0.35
EPS Est.
-$0.09
EPS Surpr.
-288.9%
Revenue
$0.00B
Q2 FY2023
May 11, 2023
EPS Actual
-$0.05
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2023
Apr 25, 2023
EPS Actual
-$0.34
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2022
Sep 30, 2022
EPS Actual
-$0.34
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2022
Aug 29, 2022Miss
EPS Actual
-$1.33
EPS Est.
-$0.08
EPS Surpr.
-1562.5%
Revenue
$0.00B
Q2 FY2022
Apr 26, 2022Miss
EPS Actual
-$1.04
EPS Est.
-$0.08
EPS Surpr.
-1195.3%
Revenue
$0.00B
Q1 FY2022
Mar 31, 2022
EPS Actual
-$0.59
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $2.00 | $1.54 | $0.91 | 0 |
| Q2 FY2024 | $1.74 | $1.34 | $0.80 | 0 |
| Q1 FY2024 | $2.04 | $1.58 | $0.93 | 1 |
| Q4 FY2023 | $-0.35 | $-0.35 | $-0.28 | 4 |
| Q3 FY2023 | $-0.35 | $-0.35 | $-0.28 | 4 |
| Q2 FY2023 | $-0.10 | $-0.08 | $-0.05 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 2 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 4 |
| Q3 FY2023 | $0.0B | $0.0B | $0.0B | 4 |
| Q2 FY2023 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q4 FY2023 | Nov 16, 2023 | -94.7% | $9.45 | $9.74 | +3.07% |
| ▼ Q3 FY2023 | Aug 9, 2023 | -288.9% | $14.54 | $14.17 | -2.54% |
| — Q2 FY2023 | May 11, 2023 | — | $11.69 | $11.29 | -3.42% |
| — Q2 FY2023 | Apr 25, 2023 | — | $10.34 | $9.73 | -5.90% |
| — Q3 FY2022 | Sep 30, 2022 | — | $1.10 | $1.08 | -1.82% |
| ▼ Q3 FY2022 | Aug 29, 2022 | -1562.5% | $1.89 | $1.82 | -3.70% |
| ▼ Q2 FY2022 | Apr 26, 2022 | -1195.3% | $3.68 | $3.50 | -4.89% |
| — Q1 FY2022 | Mar 31, 2022 | — | $4.22 | $4.12 | -2.37% |
Q4 FY2023+3.07%
Report Date
Nov 16, 2023
EPS Beat/Miss
-94.7%
Price Before
$9.45
Price After
$9.74
Q3 FY2023-2.54%
Report Date
Aug 9, 2023
EPS Beat/Miss
-288.9%
Price Before
$14.54
Price After
$14.17
Q2 FY2023-3.42%
Report Date
May 11, 2023
EPS Beat/Miss
—
Price Before
$11.69
Price After
$11.29
Q2 FY2023-5.90%
Report Date
Apr 25, 2023
EPS Beat/Miss
—
Price Before
$10.34
Price After
$9.73
Q3 FY2022-1.82%
Report Date
Sep 30, 2022
EPS Beat/Miss
—
Price Before
$1.10
Price After
$1.08
Q3 FY2022-3.70%
Report Date
Aug 29, 2022
EPS Beat/Miss
-1562.5%
Price Before
$1.89
Price After
$1.82
Q2 FY2022-4.89%
Report Date
Apr 26, 2022
EPS Beat/Miss
-1195.3%
Price Before
$3.68
Price After
$3.50
Q1 FY2022-2.37%
Report Date
Mar 31, 2022
EPS Beat/Miss
—
Price Before
$4.22
Price After
$4.12
Avg Miss Reaction-2.02%
Beat Rate0 / 8 quarters
Largest Move-5.90% (Q2 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: AMAM ends December
Ambrx Biopharma Inc. (AMAM) most recently reported earnings on November 16, 2023 for Q4 FY2023, posting EPS of $-0.37 — missing the analyst consensus of $-0.19 by -94.7%. The next AMAM earnings date is expected around September 1, 2026.
Each quarter, investors track AMAM earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AMAM revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
AMAM's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
AMAM earnings · 5 questionsAmbrx Biopharma Inc.'s next earnings report is expected around September 1, 2026. AMAM typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AMAM historically reports after market close (AMC).
AMAM earnings datewhen is AMAM earningsAMAM next earnings datewhen does AMAM report earningsAMAM earnings calendar
▸ Source: FMP · Ambrx Biopharma Inc. SEC filings · US GAAP · Ambrx Biopharma Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026